key: cord-0810095-0i258yzb
authors: Zhang, Dongdong; Wang, Zhaoye; Li, Jin; Zhu, Jianbo
title: Exploring the possible molecular targeting mechanism of Saussurea involucrata in the treatment of COVID-19 based on bioinformatics and network pharmacology
date: 2022-04-25
journal: Comput Biol Med
DOI: 10.1016/j.compbiomed.2022.105549
sha: 1a639be568acccc069ea22761300079ad21b53d0
doc_id: 810095
cord_uid: 0i258yzb

OBJECTIVE: Based on bioinformatics and network pharmacology, the treatment of Saussurea involucrata (SAIN) on novel coronavirus (COVID-19) was evaluated by the GEO clinical sample gene difference analysis, compound-target molecular docking, and molecular dynamics simulation. role in the discovery of new targets for the prevention or treatment of COVID-19, to better serve the discovery and clinical application of new drugs. MATERIALS AND METHODS: Taking the Traditional Chinese Medicine System Pharmacology Database (TCMSP) as the starting point for the preliminary selection of compounds and targets, we used tools such as Cytoscape 3.8.0, TBtools 1.098, AutoDock vina, R 4.0.2, PyMol, and GROMACS to analyze the compounds of SAIN and targets were initially screened. To further screen the active ingredients and targets, we carried out genetic difference analysis (n = 72) through clinical samples of COVID-19 derived from GEO and carried out biological process (BP) analysis on these screened targets (P ≤ 0.05)., gene = 9), KEGG pathway analysis (FDR≤0.05, gene = 9), protein interaction network (PPI) analysis (gene = 9), and compounds-target-pathway network analysis (gene = 9), to obtain the target Point-regulated biological processes, disease pathways, and compounds-target-pathway relationships. Through the precise molecular docking between the compounds and the targets, we further screened SAIN's active ingredients (Affinity ≤ −7.2 kcal/mol) targets and visualized the data. After that, we performed molecular dynamics simulations and consulted a large number of related Validation of the results in the literature. RESULTS: Through the screening, analysis, and verification of the data, it was finally confirmed that there are five main active ingredients in SAIN, which are Quercitrin, Rutin, Caffeic acid, Jaceosidin, and Beta-sitosterol, and mainly act on five targets. These targets mainly regulate Tuberculosis, TNF signaling pathway, Alzheimer's disease, Pertussis, Toll-like receptor signaling pathway, Influenza A, Non-alcoholic fatty liver disease (NAFLD), Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Fructose and mannose metabolism, and Metabolic pathways, play a role in preventing or treating COVID-19. Molecular dynamics simulation results show that the four active ingredients of SAIN, Quercitrin, Rutin, Caffeic acid, and Jaceosidin, act on the four target proteins of COVID-19, AKR1B1, C5AR1, GSK3B, and IL1B to form complexes that can be very stable in the human environment. Tertiary structure exists. CONCLUSION: Our study successfully explained the effective mechanism of SAIN in improving COVID-19, and at the same time predicted the potential targets of SAIN in the treatment of COVID-19, AKR1B1, IL1B, and GSK3B. It provides a new basis and provides great support for subsequent research on COVID-19.

As of January 28, 2022, coronavirus disease , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to be at the top of the list of worrisome diseases, partly because it spreads rapidly and is extremely difficult to control (364,191,494 confirmed cases and 5,631,457 deaths from COVID-19) [1] . However, what makes it even more troubling for the world is that COVID-19 can mutate to many types over time, such as the latest Omicron strain [2] .

Presently, the research and development of targeted vaccines against COVID-19 in most countries have problems such as complex processes, relatively high market prices (except for a few free vaccination countries), and difficulty in finding targets [3] . Therefore, these restrictions have prevented routine vaccinations in COVID-19 patients If we can discover an effective traditional Chinese medicine for the treatment of COVID-19, and clarify its effective compounds and targets for the treatment of COVID-19, it can contribute to the research and development of a global COVID-19 vaccine.

In recent years, with the advent of artemisinin [4] , berberine [5] , and other traditional Chinese medicine extracts, traditional Chinese medicine has played an increasingly important role in the treatment of refractory tumors, including common liver cancer [6] , lung cancer [7] and pan-cancer [8] . Thus, we have gradually realized the great utility of traditional Chinese medicine in cancer treatment. In previous research, we identified the effective components and mechanisms of action of traditional Chinese medicine in the treatment of non-small cell lung cancer [9] .

Saussurea involucrata (SAIN) is one of many traditional Chinese medicines. It is mainly distributed in high-altitude areas such as Xinjiang and Tibet in China. Research on the pharmacological effects of SAIN began in the 1980s [10] . There are many known pharmacological activities and effects of SAIN, but the most studied are its anti-inflammatory, antioxidant [11] , and anti-cancer effects (prostate cancer, gastric cancer, breast cancer, etc.) [12] . Its effects in other diseases (such as COVID- 19) have not been studied yet. Therefore, research is urgently needed to evaluate the efficacy of SAIN as a supplement in the treatment of Previous studies showed that Quercitrin could significantly inhibit the production of reactive oxygen species (ROS) and increase the malondialdehyde content. In the streptozotocin-induced diabetic mouse model, Quercitrin showed strong organ protection characteristics in the pancreas, liver, and kidney by improving antioxidant traits [13] , supported by the results of in vitro studies [14] . Studies in the past two years showed that the antioxidant activity of drugs was very important in the treatment of and protection against COVID-19 [15] . In clinical experiments, researchers have also modified it for the treatment of COVID-19 according to the selective antioxidant characteristics of hydrogen therapy [16] .

Caffeic acid is a well-known plant nutrient. Through further research, the beneficial effects of Caffeic acid such as antioxidant, antibacterial, and neuroprotective activities were identified and applied [17] . Jaceosidin is a natural flavonoid with anti-inflammatory, antioxidant [18, 19] , anticancer, and immunosuppressive effects [19] . However, in coronavirus research, evidence on the effects of Caffeic acid (CAFD [20] ) and Jaceosidin is still insufficient. Thus, the positive results of our research can be used as powerful evidence to prove that Caffeic acid and Jaceosidin play roles in improving Presently, studies to identify SARS-CoV-2 inhibitors have been conducted [21] . Simulation studies showed that Rutin showed the best potential effect in inhibiting SARS-CoV-2. Coupled with its strong solubility and weak lipophilicity, Rutin displayed the potential for becoming a COVID-19-targeted drug.

Network pharmacology is a new research method emerging in recent years. It was first proposed by Professor Hopkins, a pharmacologist from the University of Dundee in the United Kingdom [22] . Based on the theory of systems biology, network pharmacology is a new discipline that selects specific signal nodes for multi-targeted drug molecular design. Network pharmacology emphasizes the multi-way regulation of signaling pathways by targets to improve the therapeutic effect of drugs and reduce their toxicity and side effects, thereby improving the success rate of the clinical trials of new drugs and reducing drug research and development costs. Therefore, we used the network pharmacology method combined with bioinformatics, gene difference analysis, molecular docking, molecular dynamics simulation, and other methods to analyze the mechanism of action of the active ingredients and targets of SAIN active ingredients in the treatment and prevention of COVID-19.

In this study, for the first time, we identified the components of SAIN that could effectively treat or prevent COVID-19, namely Rutin, Jaceosidin, CAFD, and Quercitrin. Moreover, our findings are consistent with the findings of previous research on Rutin and CAFD [23, 24] , Jaceosidin [25] , and Quercitrin [26, 27] ). However, most of these studies were conducted using the usual basic experimental methods. Different from the research of others, our research was based on a computer deep learning model [28, 29, 30] and the use of an improved network pharmacology process to simulate the existing state of these compounds in the standard human environment after binding to their target proteins. Then, the most suitable active ingredients for the treatment or prevention of COVID-19 were selected.

Traditional Chinese Medicine System Pharmacology Database and Analysis Platform TCMSP (https://tcmsp-e.com/) database [31] is one of the most commonly used databases for the screening of active ingredients in traditional Chinese medicine. OB and drug similarity (DL) parameters, these two parameters have a very important role in the evaluation of drug efficacy, only when these two values exceed a certain value (OB≥25% and DL>0 or OB>0% and DL ≥ 0.18), can effectively reflect the drug-like properties of certain compounds.

Among them, the calculation of the DL value of this system follows formula (1) . To obtain the target drug, only when the lead compound is chemically easy to be synthesized and has the properties of ADMET (absorption, distribution, metabolism, excretion, and toxicity), the DL value will work. (1) X represents the descriptive index of all compounds in SAIN in formula (1), and y represents the average drug similarity index of these compounds from the DrugBank (https://www.drugbank.ca/) database [32] .

The lipid-water partition coefficient log ⁄ reside used the distribution coefficient of the drug in the n-octanolwater system, which is wideused as a measure of the hydrophobicity of chemical compounds. The main driving force of controls the binding effect of the compounds-target. log ⁄ is one of the representation methods of log ⁄ .

Generally, the range of the log ⁄ value we require is between -0.4 and 5.6. The calculation of log ⁄ follows formula (2): = log log (2) CO represents the equilibrium concentration of the drug in the oil phase, and CW represents the equilibrium concentration of the drug in the water phase in formula (2) . The log ⁄ value indicates the hydrophobicity of the solute. The larger the log ⁄ , the stronger the hydrophobicity, and vice versa.

To study the mechanism of SAIN's active ingredient targeted treatment of COVID-19, first of all, we must get the targets J o u r n a l P r e -p r o o f that all active ingredients can act on, we need to get the verified COVID-19 targets then. Only by finding the common part of these two kinds of targets can we continue to study this experiment.

The above-obtained SAIN active ingredients were searched in the TCMSP database to obtain all targets corresponding to SAIN chemical ingredients, which were merged with the COVID-19 targets we obtained in the DisGeNET database (https://www.disgenet.org/) [33] , and then take venn coincidence to obtain the final required disease target information.

To show the corresponding relationship between SAIN and its active components, targets and COVID-19 clearly, we use Cytoscape 3.8.0 software [34] to visualize the above active compounds and targets to construct a compounds-target-disease network (C-T-D network) to obtain the C-T-D network relationship diagram we need, In this network diagram, we use different node shapes and colors to represent each content. So far, we have completed the initial screening of SAIN's COVID-19-related active ingredients.

To obtain disease targets with interaction relationships, we performed protein interaction analysis (PPI analysis) on all the initially screened targets, we preset the enrichment p value < 1.0e-16 as the analysis condition. After PPI network analysis, we obtained the interaction network of all proteins. According to this network diagram, we got COVID-19 targets that were further screened.

GEO database( https://www.ncbi.nlm.nih.gov/geo/)from NCBI [35] , different from TCGA database, GEO database not only contains cancer-related clinical information, but also has many non-cancer clinical information, which makes GEO database more perfect in the provision of clinical case information.

To further screen the active ingredients and their targets that we have preliminarily screened, we obtained enough COVID-19 clinical case samples from the GSE148829 data set of geo database (The data set contains 349 clinical samples, of which 72 samples of human COVID-19 infected persons were selected).

Through the gene difference analysis of GSE clinical samples, we randomly selected samples to draw an intuitive gene difference heat map for target screening again.

To evaluate the interaction between the targets screened above, a protein interaction network and an active compoundstarget-pathway network (C-T-P network) were constructed. To explore the biological processes and pathways involved in each target in vivo, DAVID (https://david.ncifcrf.gov/) database [36] retrieved the data of the target gene, we performed biological process (BP) analysis in GO (Gene Ontology) analysis and KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment analysis. Among them, the FDR of GO analysis is less than or equal to 0.05, and the FDR of KEGG enrichment analysis is less than or equal to 0.05, all of which meet the requirements and statistical significance of genes significantly enriched in vivo.

The FDR value is corrected for the P-value, and the results screened with it are more accurate. Therefore, this step aims to obtain the biological process and in vivo pathway of the target action, which provides a basis for subsequent research.

Molecular docking [37] is a method for drug design through the characteristics of receptors and the interaction between receptors and drug molecules. A theoretical simulation method that mainly studies the interactions between molecules (such as ligands and receptors) and predicts their binding modes and affinities. In recent years, molecular docking methods have become an important technology in the field of computer-aided drug research [38] .

The precise molecular docking between the active ingredients of SAIN and the COVID-19 target is carried out by tools such as AutoDock Vina software [39] and PyMol software [40] . Whether the effect of 19 is reliable, and further exclude compounds in SAIN that are less effective against COVID-19.

Based on molecular docking and GSE gene difference analysis, we verified the results by molecular dynamics simulation J o u r n a l P r e -p r o o f (MD simulation). MD simulation is a means of simulating the movement of small molecules in the body environment by computer. The MD simulation was performed with Gromacs software [41] , the physical conditions were set as constant temperature (310K), constant pressure (101kPa), and periodic boundary conditions, and the TIP3P water model was used to simulate the human environment in a neutral sodium chloride solution of 0.145mol/L. , after the state balance of all environments, we use the compounds-target complex system that has been screened to perform 50ns MD simulation, in which, every 10ps, a confirmation storage calculation is performed, and the RMSD of the MD simulation results (Root mean Square deviation), RMSF (Root Mean Square Fluctuation), Rg value (Radius of gyration) and SASA (Solvent accessible surface area) were analyzed and visualized using the Gromacs embedded program and VMD. We know that the radius of gyration Rg of the protein reflects the protein The volume and structural state of macromolecules, the larger the Rg value of the same system, the expansion of the system occurred during the MD process, and SASA is an important means to describe the hydrophobicity of proteins, and the hydrophobicity of amino acid residues is an important factor affecting protein folding. physical action. The formulas of RMSD and RMSF areas (3) and (4). 

We collected a total of 55 known active ingredients in SAIN from the TCMSP database, including alkaloids, lipids, flavonoids, and flavonoids. Fifteen effective drug-like compounds were screened from the 55 SAIN compounds under different screening conditions. The screening details of these 15 compounds are shown in Table 1 . J o u r n a l P r e -p r o o f

After deduplication screening, we obtained a total of 109 targets in the SAIN active ingredients using the TCMSP database. We also obtained 1843 non-duplicated COVID-19 targets using the latest COVID-19 target data from the DisGeNET database. Then, we generated a Venn diagram of the SAIN and COVID-19 coincident targets (Fig.1) . The Venn diagram showed that SAIN and COVID-19 had 29 coincident targets (Table 2) . NOS1  BCL2  FCER2  NOS2  BID  GFAP  NOS3  BTK  GSK3B  NR1I2  C5AR1  HTR3A  PDE4A  CASP3  IL1B  PIK3CG  CASP8  IL6  PON1  CYP3A4 INS  PPARG  DPEP1  JUN  TGFB1  DPP4 KCNMA1

To obtain disease targets with interactive relationships, we performed a PPI network analysis on the 29 targets that were initially screened and obtained an interactive relationship network diagram of the proteins encoded by the 29 genes ( Fig. 2A) . The network showed that 5-hydroxytryptamine receptor 3A (HTR3A) had no interaction with the remaining 28 targets, indicating that HTR3A did not play a strong role in multi-targeted therapy for COVID-19. Thus, it was discarded and a new PPI network was constructed using the remaining 28 targets (Fig. 2B) , from which we obtained the further screened COVID-19 targets. Targets such as caspase-8 (CASP8) and peroxisome proliferator-activated receptor-gamma (PPARG) may also play significant roles in COVID-19 symptoms, although some proteins did not clearly appear to interact with others. Important roles for aldo-keto reductase family 1 member B1 (AKR1B1), C5a anaphylatoxin chemotactic receptor 1 (C5AR1), and BH3-interacting domain death agonist (BID) targets were also identified

To ensure the accuracy of the experimental data, we further screened the compounds and targets. Through the GEO database, we obtained a total of 57,910 COVID-19-related disease genes from the GSE148829 dataset. All these COVID-19 gene expressions had high reference values. These genes corresponded to 72 COVID-19 clinical infection samples in the GSE148829 dataset. We selected the expression data of the 28 genes we needed from these 72 COVID-19 case samples. A heatmap of gene differences was then drawn using the R 4.0.2 visual programming language (Fig. 3) .

According to the gene difference analysis of the GSE clinical samples, we excluded 19 targets with no obvious difference among the remaining 28 targets. Thus, 9 COVID-19 differentially expressed targets remained. The expression levels of these 9 targets ranked from high to low were AKR1B1, C5AR1, BID, CASP3, CASP8, IL1B, IL6, JUN, and GSK3B, among which, the expression level of the 3 targets AKR1B1, C5AR1, and BID in COVID-19 patients was significantly higher than that of the other targets. After mapping these 9 targets to the active ingredients of SAIN, we screened out 6 more accurate SAIN ingredients from the 15 SAIN active ingredients.

To map the 6 effective compounds in SAIN and their one-to-one relationship with COVID-19 intersection targets, we used Cytoscape software to construct a C-T-D network (Fig. 4) . Through the C-T-D network, we found that the 6 ranking compounds with strong effects on the target were Rutin, dehydrocostus lactone, beta-sitosterol, Jaceosidin, Quercitrin, and CAFD. 

From the gene difference analysis of the GSE clinical samples, we used the 9 differentially expressed targets of COVID-19, BID, CASP3, CASP8, IL1B, IL6, JUN, AKR1B1, C5AR1, and GSK3B. Since IL6 levels were significantly elevated in complex COVID-19 cases [42] , the researchers assessed the possibility of IL6 as a therapeutic target for COVID-19. A previous study [43] also reported that vitamin D may reduce the mortality of COVID-19 patients by regulating the IL1B protein content.

We performed gene ontology (GO) biological process (BP) analysis on the remaining 9 targets and drew a chord diagram representing 21 biological regulatory processes (Fig. 5) .

The biological processes in GO enrichment analysis showed that 2 of the 9 COVID-19 targets (IL6 and IL1B) we screened positively regulated interleukin-6 production and nitric oxide (NO) biosynthesis, accelerating NO biosynthesis and IL6 production.In addition, CASP3 and CASP8 in these targets could also kill tumor cells and mediate inflammatory responses by regulating the GO:0034612 process (response to tumor necrosis factor).

To maintain the reliability and statistical significance of the data, we performed a Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis at P < 0.005 in the String and DAVID databases, and displayed the 26 pathways in the comprehensively considered the results in the form of a heatmap (Fig. 6) . We performed cluster analysis on the 26 KEGG pathways, which showed that the clusters were divided into 4 types. KEGG enrichment analysis revealed that most of the pathways were related to inflammation, bacterial infection, influenza, tuberculosis, metabolism, and cancer. Nineteen were mainly enriched for non-alcoholic fatty liver disease (NAFLD), neuroactive ligand-receptor interaction, pertussis, the tumor necrosis factor (TNF) signaling pathway, tuberculosis, influenza A, and fructose and mannose metabolism.

First, from the C-T-P network diagram, according to the number of compounds, targets, and proteins, we ranked the 6 active compounds of SAIN as Rutin, beta-sitosterol, dehydrocostus lactone, Jaceosidin, Quercitrin, and CAFD. According to the number of target regulatory pathways, we ranked the 9 targets of COVID-19 as IL6, IL1B, CASP3, CASP8, JUN, BID, GSK3B, AKR1B1, and C5AR1, and some of the 26 pathways were ranked as NAFLD, tuberculosis, TNF signaling pathway, influenza A, and pertussis, etc. However, although these targets and pathways may contribute to the effects seen in COVID-19 patients, the strength and accuracy of their contributions were still not easily distinguishable. Therefore, further analysis and validation are required.

Through the series of analyses, screening, and verification work above, we identified the target sites of 6 SAIN compounds, and these 6 compounds could act on multiple targets in COVID-19. Among them, beta-sitosterol could target CASP8, JUN, and CASP3; dehydrocostus lactone could target CASP8, CASP3, and BID; Rutin could target C5AR1, IL1B, IL6, and CASP3; Jaceosidin could target GSK3B and CASP3, CAFD, and Quercitrin could only target AKR1B. Thus, by looking at these correspondences and the known effects of the targets, we inferred that Rutin, dehydrocostus lactone, betasitosterol, and Jaceosidin may be effective COVID-19 treatments.

After obtaining this information, we used Chemdraw 19.0 software [44] to draw the structures of the 6 compounds, saved them as mol2 files, and used the PDB (https://www.rcsb.org/) database [45] to select the corresponding compounds according to their structures. The tertiary structure of the protein with ligands was obtained and the PDB file was downloaded. The protein PDB file was processed using Discovery Studio software [46] (to remove water molecules and redundant structures, etc.), and the two file formats were saved as pdbqt using AutoDock software. Ligands, coordinate positions (x, y, z), and compounds in the file were selected, filtered, and ranked by hydrogen bond distance, and the tertiary structures were predicted using X-ray diffraction or solution nuclear magnetic resonance (NMR). Then, we used AutoDock and AutoDock Vina to perform molecular docking between the compounds and targets. The docking results are shown in Table 3 and Fig.8 . We ranked the docking results and selected 6 compound-target complex pairs with binding energy≤-J o u r n a l P r e -p r o o f 7.2kcal/mol using the PyMol process and visualized the results (Fig.9) . To ensure the availability and reference value of the data, we set the coordinates (x, y, z) according to the structural size of the compounds themselves. It is known that the larger this coordinate value is, the greater the docking affinity, indicating that compounds with tighter binding to the target would be more effective. Therefore, the coordinate values we used were the most appropriate for the composition itself. The docking results showed that the best binding energy (kcal/mol) of a compound and target was -11.5kcal/mol, and the worst was -5.3kcal/mol.

The visualization results indicated that the 4 active ingredients of SAIN Quercitrin, Rutin, CAFD, and Jaceosidin could be well combined with the corresponding targets. Among them, Quercitrin could bind to the amino acid residues TRY-219, ARG-217, TRP-295, ASN-294, and ARG-296 with an average hydrogen bond distance of 3.04 Å. CAFE could bind to the amino acid residues ASN-292, THR191, GLU-193, ASN-294, and ASN-294 of AKR1B1 protein. bound with an average hydrogen bond distance of about 3.15 Å, suggesting that Quercitrin was better than CAFD. Rutin bound the amino acid residues LEU-209, ALA-128, TRP-213, and THR-217 of C5AR1 protein with an average hydrogen bond distance of about 3.025 Å. Rutin bound to the amino acid residues MET-20 and MET-20 of IL1B protein, and Rutin bound to LYS-63 with an average hydrogen bond distance of about 2.4 Å. The binding of Rutin to IL1B was stronger than to C5AR1. Jaceosidin bound to the amino acid residues ALA-232 and LYS181 of GSK3B protein with an average hydrogen bond distance of about 3.15 Å, and beta-sitosterol bound to the amino acid residue ARG-413 of CASP8 protein with a hydrogen bond distance of 2.9Å.

MD results such as RMSD, RMSF, Rg value, and SASA provide an important basis for measuring the stability of complex systems of compounds and proteins, and the stability of protein tertiary structures after combining small molecules, the hydrophobicity of amino acid residues, etc. Therefore, with a binding energy of≤-7.6kcal/mol as the limit, we selected the first 5 molecular docking systems for MD simulations. To make these data more intuitive, we visualized their output data (Fig. 10) . The RMSD results of the MD simulations (shown as a red, broken line in Fig.10) showed that in the 5 MD systems of compound and target complexes, the overall performance of the C5AR1 and Rutin complex system was not good. The large RMSD fluctuations, large gyration radius, large RMSF fluctuation, and poor SASA performance indicated that the system did not show an effective inhibitory effect against COVID-19.

For the two complex systems (purple and blue broken lines in Fig.10 ) formed by AKR1B1 and quercetin and CAFD, we observed that 4 experimental RMSD, Rg, RMSF, and SASA results in the AKR1B1 and quercetin system were higher than those for AKR1B1 and CAFD. The system formed with acid had better protein hydrophobicity and a more stable tertiary structure, but both systems performed well. The binding energy data of these two systems were also ideal; that is, AKR1B1 was a possible novel therapeutic target for COVID-19. We confirmed that the 2 SAIN compounds Quercitrin and CAFD, could target the AKR1B1 protein well.

In the 4 aspects of RMSD, Rg, RMSF, and SASA, the MD system (green broken line in Fig.10 ) formed by GSK3B and Jaceosidin showed a relatively good state; that is, the system could exist stably without affecting the structure itself or other proteins. The last MD system was IL1B and Rutin. This system had the most stable RMSD and RMSF, and the smallest Rg (indicating that the system would not swell) and SASA values (the amino acid residues were the most hydrophobic). Thus, this system was the best in all aspects. Therefore, the 4 active ingredients of SAIN, Quercitrin, Rutin, CAFD, and Jaceosidin, could play a role in improving or treating COVID-19 to a certain extent by acting on the 4 target proteins AKR1B1, C5AR1, GSK3B, and IL1B.

NAFLD is a global chronic disease that is part of metabolic syndrome [47] . NAFLD is also a very high-risk factor for contracting the SARS-CoV-2 virus, and there is growing evidence [48, 49, 50] that COVID-19 causes liver damage" or "and there is growing evidence [48, 49, 50] that some effects of COVID-19 are inseparable from liver damage. There is also evidence [51] , that patients infected with COVID-19 are more susceptible to underlying metabolic diseases. A study by Ji et al. [52] of more than 200 patients with COVID-19 and NAFLD reported that approximately 75% of the patients had varying degrees of liver damage during hospitalization, mainly mild hepatocyte damage, manifested as elevated levels of serum C-reactive protein and alanine aminotransferase (ALT)" or "manifested as elevated levels of serum alanine aminotransferase (ALT), 3% of the COVID-19 patients in the population presented with ductal or mixed liver injury, and approximately onethird of the patients had persistent, abnormal liver function from admission to the last day of follow-up. The authors also noted an association between COVID-19 disease progression and age (over 60), gender (male), body mass index (higher), and NAFLD, among others. Finally, the authors concluded that NAFLD was an independent risk factor for developing Our study showed that 2 proteins, IL6 and IL1B, positively regulated 2 biological processes, GO:0032755 and GO:0045429 associated with accelerating NO biosynthesis and IL6 production. Akaberi et al. [53] demonstrated that NO derived from S-nitroso-N-acetyl-penicillamine (SNAP) could delay or completely prevent the development of SARS-CoV-2 virus cytopathic effects in treated cells, and the observed protection was related to the level of viral replication inhibition. Therefore, amid the COVID-19 pandemic, the inhalation of NO gas has emerged as a possible treatment modality, which increases oxygenation in patients and may lead to better clinical outcomes [54] . Rutin, a compound in SAIN, effectively targeted IL1B and IL6 (including MD and MD simulation), and the cytokines IL1B and IL6 were both key targets that could regulate NAFLD. It has been reported [55] that variations in the IL1B and IL6 genes may be associated with disease susceptibility and cytokine storm and/or COVID-19 complications, and rapid and effective vitamin D supplementation may reduce symptoms and mortality in COVID-19 patients by altering serum IL1B levels [56] .

GSK3B, glycogen synthase kinase-3 beta, has two forms in vivo, the phosphorylated and dephosphorylated forms, and when it is phosphorylated, it upregulates the expression of IL6 and TNF. Angiotensin-converting enzyme 2 (ACE2) was highly expressed in tissue samples from 15 human organs, including the heart and kidney, as well as the main target cells of SARS-CoV-2 and alveolar epithelial cells at the main site of injury [57] , indicating that ACE2 is a substance that can facilitate the entry of the SARS-CoV-2 virus into the human body. Therefore, we can greatly reduce the risk of SARS-CoV-2 virus infection by reducing the expression of ACE2 in SARS-CoV-2 target cells (gut and alveolar epithelial cells).

Our study showed that Jaceosidin, a compound in SAIN, could target and stabilize GSK3B; that is, Jaceosidin could upregulate the expression of GSK3B to regulate the NAFLD and influenza A pathways. When the expression of GSK3B increases, it will simultaneously increase the expression of IL6 and TNF. Studies showed that the upregulation of inflammatory factors such as IL6, IL1B, and TNF reduced the expression of ACE2 [58] , while the latest SARS-CoV-2 virus did not. Therefore, taking oral preparations made from SAIN or the single-use of Jaceosidin can effectively prevent SARS-CoV-2 infection.

This study focused on the role of several active ingredients in SAIN, a comprehensive Chinese medicine agent. The 6 SAIN compounds Quercitrin, CAFD, Jaceosidin, Rutin, beta-sitosterol, and dehydrocostus lactone could be used as effective substances against the 9 targets AKR1B1, GSK3B, IL1B, C5AR1, CASP8, IL6, CASP3, BID, and JUN. That is, when COVID-19 patients are administered SAIN or these single compounds together, the greatest preventive or therapeutic effects of SAIN can be achieved.

The complexity and variability of COVID-19 have prevented us from explaining it in terms of changes in a single gene. Therefore, treatment for COVID-19 cannot be achieved through one approach, but requires multiple approaches, such as combination therapy with multiple targets. The 6 quercetin, CAFD, Jaceosidin, Rutin, beta-sitosterol, and dehydrocostus lactone compounds in SAIN could bind the AKR1B1, GSK3B, IL1B, C5AR1, CASP8, IL6, CASP3, BID, and JUN targets and function as biological processes and pathways by participating in GO:0032755, GO:0045429, NAFLD, neuroactive ligand-receptor interaction, pertussis, the TNF signaling pathway, tuberculosis, and influenza A. However, the role of the inhibitors or activators in the prevention and treatment of COVID-19 under the combined action of these processes is unknown. Therefore, for COVID-19, a complete cure still requires the joint efforts of researchers in various fields.

The hierarchy set in this paper provides references and guidance for future research. In recent years, in the field of molecular docking, generally, the binding of a single compound to the target protein has been studied. Although many compounds sometimes bind to the same protein, there will be no additional binding energy. Thus, future research should focus on the calculation program and binding effect of molecular docking. Similarly, in terms of molecular dynamics simulation, although it describes the movement of a compound and protein in the same system, it does not clearly show the interaction between the compound and other proteins (inevitable in the actual environment). Therefore, these problems will be taken into account in future research.

We confirm that all methods in the manuscript are carried out in accordance with the relevant guidelines Ethics approval and consent to participate: Not applicable

Availability of data and materials: The datasets generated and/or analysed during the current study are not publicly available due the limited scope of data availability, these data are used under the license of this study and are not disclosed,but are available from the author[sedate@stu. shzu.edu.cn (Dongdong Zhang)] on reasonable request. 

WHO. WHO Coronavirus (COVID-19) Dashboard. 28,1

Chenyue Sun, It is not the time to relax yet: masks are still needed for the Omicron variant of SARS-CoV-2, Public Health

COVID-19 Vaccines

Artemisinin-A Gift from Traditional Chinese Medicine to the World (Nobel Lecture)

Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. The lancet

Traditional Chinese medicine for prevention and treatment of hepatocarcinoma: From bench to bedside

Traditional Chinese medicine and lung cancer-From theory to practice

New Perspective on the Anti-Tumor Mechanism of A Traditional Natural Medicine

Screening the components of Saussurea involucrata for novel targets for the treatment of NSCLC using network pharmacology

Studies on pharmacological actions of Saussurea involucrata Kar et Kir ex Maxim (author's transl)

Therapeutic Effects of Saussurea Involucrata Injection against Severe Acute Pancreatitis-Induced Brain Injury in Rats

The effect of methanol extract from Saussurea involucrata in the lipopolysaccharide-stimulated inflammation in cultured RAW 264.7 cells

Network pharmacology

Bee Honey, and Their Components Protect against Coronavirus Disease 2019 (COVID-19): A Review of In Silico

Optimization and evaluation of propolis liposomes as a promising therapeutic approach for COVID-19

Phytocompounds from Anvillea radiata as promising anti-Covid-19 drugs: in silico studies and in vivo safety assessment

Repurposing of FDAapproved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease

Identification of phytocompounds from Houttuynia cordata Thunb. as potential inhibitors for SARS-CoV-2 replication proteins through GC-MS/LC-MS characterization, molecular docking and molecular dynamics simulation

Review on machine and deep learning models for the detection and prediction of Coronavirus

A prospective and comparative study of machine and deep learning techniques for smart healthcare applications

A comparative study of different machine learning techniques for brain tumor analysis

TCMSP: a database of systems pharmacology for drug discovery from herbal medicines

DrugBank 5.0: a major update to the DrugBank database

The DisGeNET knowledge platform for disease genomics: 2019 update

Cytoscape: a software environment for integrated models of biomolecular interaction networks

NCBI GEO: archive for functional genomics data sets--update

Database for Annotation, Visualization, and Integrated Discovery

Molecular Docking: Shifting Paradigms in Drug Discovery

Molecular Docking in Formulation and Development

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Ligand docking and binding site analysis with PyMOL and Autodock/Vina

Molecular Dynamics Simulation of Proteins

Interleukin-6 in Covid-19: A systematic review and meta-analysis

Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin -LL37, and ICAM1

PTGS2 (Cyclooxygenase-2) expression and survival among colorectal cancer patients: a systematic review

MMP2 Modulates Inflammatory Response during Axonal Regeneration in the Murine Visual System

Computer review of ChemDraw Ultra 12.0

NAFLD and COVID-19: a Pooled Analysis

Liver injury in COVID-19: management and challenges

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies

COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics

Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study

Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro

MT Home Nitric Oxide Therapy for COVID

Genetics Insight for COVID-19 Susceptibility and Severity: A Review

Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1

Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers

Tumor necrosis factoralpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)

Quercitrin offers protection against brain injury in mice by inhibiting oxidative stress and inflammation

Chemical constituents from Polygonum capitatum and their antioxidation activities in vitro

Use of succulent bio-medicines to control

New Approaches for Hydrogen Therapy of Various Diseases

CAFD Phenethyl Ester: A Review of Its Antioxidant Activity, Protective Effects against Ischemiareperfusion Injury and Drug Adverse Reactions

Antioxidant and Anti-inflammatory activities of Jaceosidin from Artemisia princeps Pampanini SJ-1 (Sajabalssuk

Natural Flavone Jaceosidin is a Neuroinflammation Inhibitor

CAFD derivatives (CAFDs) as inhibitors of SARS-CoV-2: CAFDs-based functional foods as a potential alternative approach to combat COVID-19

SARS-CoV-2 Inhibitors fromNigella Sativa

J o u r n a l P r e -p r o o f